Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06667272 in Healthy Adults
NCT03126149Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06667272 in Nonalcoholic steatohepatitis (NASH) (2 cohorts), sponsored by Pfizer. Primary endpoint: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) or other safety concerns. Started May 2017; status: completed.
02
Drugs
PF-06667272
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03126149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126149.